RATIONALE: Cannabis dependence is a growing problem among individuals who use marijuana frequently, and genetic differences make some users more liable to progress to dependence. The identification of intermediate phenotypes of cannabis dependence may aid candidate genetic analysis. Promising intermediate phenotypes include craving for marijuana, withdrawal symptoms after abstinence, and sensitivity to its acute effects. A single nucleotide polymorphism (SNP) in the gene encoding for fatty acid amide hydrolase (FAAH) has demonstrated association with substance use disorder diagnoses, but has not been studied with respect to these narrower phenotypes. FAAH is an enzyme that inactivates anandamide, an endogenous agonist for CB(1) receptors (to which Delta(9)-tetrahydrocannabinol binds). CB(1) binding modulates mesocorticolimbic dopamine release, which underlies many facets of addiction. OBJECTIVES: The SNP, FAAH C385A (rs324420), was examined to determine whether its variance was associated with changes in craving and withdrawal after marijuana abstinence, craving after cue exposure, or sensitivity to the acute effects of marijuana. MATERIALS AND METHODS: Forty daily marijuana users abstained for 24 h, were presented with a cue-elicited craving paradigm and smoked a marijuana cigarette in the laboratory. RESULTS: C385A variance was significantly associated with changes in withdrawal after abstinence, and happiness after smoking marijuana in the predicted directions, was associated with changes in heart rate after smoking in the opposite of the predicted direction, and was not associated with changes in craving or other acute effects. CONCLUSIONS: These data lend support to some previous association studies of C385A, but suggest that further refinement of these intermediate phenotypes is necessary.
RATIONALE: Cannabis dependence is a growing problem among individuals who use marijuana frequently, and genetic differences make some users more liable to progress to dependence. The identification of intermediate phenotypes of cannabis dependence may aid candidate genetic analysis. Promising intermediate phenotypes include craving for marijuana, withdrawal symptoms after abstinence, and sensitivity to its acute effects. A single nucleotide polymorphism (SNP) in the gene encoding for fatty acid amide hydrolase (FAAH) has demonstrated association with substance use disorder diagnoses, but has not been studied with respect to these narrower phenotypes. FAAH is an enzyme that inactivates anandamide, an endogenous agonist for CB(1) receptors (to which Delta(9)-tetrahydrocannabinol binds). CB(1) binding modulates mesocorticolimbic dopamine release, which underlies many facets of addiction. OBJECTIVES: The SNP, FAAH C385A (rs324420), was examined to determine whether its variance was associated with changes in craving and withdrawal after marijuana abstinence, craving after cue exposure, or sensitivity to the acute effects of marijuana. MATERIALS AND METHODS: Forty daily marijuana users abstained for 24 h, were presented with a cue-elicited craving paradigm and smoked a marijuana cigarette in the laboratory. RESULTS: C385A variance was significantly associated with changes in withdrawal after abstinence, and happiness after smoking marijuana in the predicted directions, was associated with changes in heart rate after smoking in the opposite of the predicted direction, and was not associated with changes in craving or other acute effects. CONCLUSIONS: These data lend support to some previous association studies of C385A, but suggest that further refinement of these intermediate phenotypes is necessary.
Authors: B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman Journal: Proc Natl Acad Sci U S A Date: 2001-07-24 Impact factor: 11.205
Authors: Carl L Hart; Amie S Ward; Margaret Haney; Sandra D Comer; Richard W Foltin; Marian W Fischman Journal: Psychopharmacology (Berl) Date: 2002-09-14 Impact factor: 4.530
Authors: Edward G Singleton; Adria J M Trotman; Marina Zavahir; Richard C Taylor; Stephen J Heishman Journal: Exp Clin Psychopharmacol Date: 2002-02 Impact factor: 3.157
Authors: Jack C Sipe; Kyle Chiang; Alexandra L Gerber; Ernest Beutler; Benjamin F Cravatt Journal: Proc Natl Acad Sci U S A Date: 2002-06-11 Impact factor: 11.205
Authors: L Cinnamon Bidwell; Jarrod M Ellingson; Hollis C Karoly; Sophie L YorkWilliams; Leah N Hitchcock; Brian L Tracy; Jost Klawitter; Cristina Sempio; Angela D Bryan; Kent E Hutchison Journal: JAMA Psychiatry Date: 2020-08-01 Impact factor: 21.596
Authors: L Cinnamon Bidwell; Jane Metrik; John McGeary; Rohan H C Palmer; S Francazio; Valerie S Knopik Journal: J Stud Alcohol Drugs Date: 2013-11 Impact factor: 2.582
Authors: Rohan H C Palmer; John E McGeary; Valerie S Knopik; L Cinnamon Bidwell; Jane M Metrik Journal: Am J Drug Alcohol Abuse Date: 2019-06-11 Impact factor: 3.829
Authors: Francesca M Filbey; Joseph P Schacht; Ursula S Myers; Robert S Chavez; Kent E Hutchison Journal: Neuropsychopharmacology Date: 2009-12-09 Impact factor: 7.853
Authors: Isabelle Boileau; Esmaeil Mansouri; Belinda Williams; Bernard Le Foll; Pablo Rusjan; Romina Mizrahi; Rachel F Tyndale; Marilyn A Huestis; Doris E Payer; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong Journal: Biol Psychiatry Date: 2016-04-25 Impact factor: 13.382
Authors: Caitlin E Carey; Arpana Agrawal; Bo Zhang; Emily D Conley; Louisa Degenhardt; Andrew C Heath; Daofeng Li; Michael T Lynskey; Nicholas G Martin; Grant W Montgomery; Ting Wang; Laura J Bierut; Ahmad R Hariri; Elliot C Nelson; Ryan Bogdan Journal: J Abnorm Psychol Date: 2015-11